MIEN1

Summary

MIEN1 (migration and invasion enhancer 1, HGNC:28230) is a protein-coding gene on chromosome 17q12, encoding Migration and invasion enhancer 1 (Q9BRT3). Increases cell migration by inducing filopodia formation at the leading edge of migrating cells.

Involved in negative regulation of apoptotic process; positive regulation of cell migration; and positive regulation of filopodium assembly. Located in cytoplasmic side of plasma membrane and cytosol.

Source: NCBI Gene 84299 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 10 total
• MANE Select transcript: NM_032339

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28230
Approved symbol	MIEN1
Name	migration and invasion enhancer 1
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	MGC14832, ORB3, XTP4, C35, Rdx12
Ensembl gene	ENSG00000141741
Ensembl biotype	protein_coding
OMIM	611802
Entrez	84299

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000394231, ENST00000469568, ENST00000474210, ENST00000498164, ENST00000577810, ENST00000582963, ENST00000935317, ENST00000935318

RefSeq mRNA: 2 — MANE Select: NM_032339 NM_001330206, NM_032339

CCDS: CCDS11344, CCDS82115

Canonical transcript exons

ENST00000394231 — 4 exons

Exon	Start	End
ENSE00000950667	39730194	39730291
ENSE00001848841	39730407	39730532
ENSE00003480361	39728510	39729605
ENSE00003685036	39729685	39729761

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 97.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.2147 / max 275.7347, expressed in 1823 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165623	29.4283	1820
165622	4.6557	1726
165621	1.1307	531

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	97.66	gold quality
putamen	UBERON:0001874	97.44	gold quality
caudate nucleus	UBERON:0001873	97.40	gold quality
ileal mucosa	UBERON:0000331	97.17	gold quality
nucleus accumbens	UBERON:0001882	96.62	gold quality
apex of heart	UBERON:0002098	96.55	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.53	gold quality
lower esophagus mucosa	UBERON:0035834	96.45	gold quality
amygdala	UBERON:0001876	95.94	gold quality
granulocyte	CL:0000094	95.93	gold quality
anterior cingulate cortex	UBERON:0009835	95.93	gold quality
spinal cord	UBERON:0002240	95.89	gold quality
prefrontal cortex	UBERON:0000451	95.86	gold quality
body of stomach	UBERON:0001161	95.70	gold quality
right frontal lobe	UBERON:0002810	95.70	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.64	gold quality
kidney epithelium	UBERON:0004819	95.61	gold quality
substantia nigra	UBERON:0002038	95.56	gold quality
hypothalamus	UBERON:0001898	95.50	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.38	gold quality
metanephros cortex	UBERON:0010533	95.35	gold quality
right atrium auricular region	UBERON:0006631	95.27	gold quality
adenohypophysis	UBERON:0002196	95.20	gold quality
adult mammalian kidney	UBERON:0000082	95.09	gold quality
transverse colon	UBERON:0001157	95.05	gold quality
islet of Langerhans	UBERON:0000006	95.02	gold quality
midbrain	UBERON:0001891	94.99	gold quality
saliva-secreting gland	UBERON:0001044	94.98	gold quality
cardiac atrium	UBERON:0002081	94.96	gold quality
middle temporal gyrus	UBERON:0002771	94.95	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-75688	yes	1769.16
E-CURD-10	no	226.81
E-CURD-112	no	2.48
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

52 targeting MIEN1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-609	99.82	64.26	505
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-5100	99.11	67.52	1098
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-502-5P	98.77	66.51	906
HSA-MIR-6769B-5P	98.73	64.91	1092

Literature-anchored findings (GeneRIF, showing 19)

• MGC14832 gene is located within human chromosome 17q12 amplicon, including PPP1R1B, STARD3, TCAP, PNMT, ERBB2, MGC14832 and GRB7 genes. PPP1R1B ~ ERBB2 ~ GRB7 locus is amplified in human gastric cancer and breast cancer. (PMID:12739007)
• Oncogenomic recombination hotspot around the PPP1R1B-STARD3-TCAP-PNMT-PERLD1-ERBB2-C17orf37-GRB7 amplicon at human chromosome 17q12 is closely linked to evolutionary recombination hotspot around the GSDML-GSDM locus. (PMID:15010812)
• Data strongly suggest C17orf37 overexpression in prostate cancer functionally enhances migration and invasion of tumor cells, and is an important target for cancer therapy. (PMID:19503095)
• Inhibition of C35 gene expression by small interfering RNA induces apoptosis of breast cancer cells. (PMID:21068479)
• prenylation is required for the function of the C17orf37 protein in cancer cells (PMID:21628459)
• Results suggest that MIEN1 may have an important regulatory role in phosphorylation of AKT with its redox potential. (PMID:23284973)
• results suggest that DeltaNp73 might cooperate with C35 to promote tumour progression and contribute to cisplatin resistance in ovarian cancer cells. (PMID:23880825)
• While MIEN1 is a direct target of miR-940, miR-940 alters MIEN1 RNA. (PMID:25406943)
• MIEN1 expression not only positively correlates with oral cancer progression but also seems to be a critical molecular determinant in migration and invasion of oral cancer cells. (PMID:25996585)
• C35 might serve as a biomarker or therapeutic target for management of colorectal cancer. (PMID:26173296)
• MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. (PMID:26272794)
• In conclusion, this study revealed that miR-26b suppresses NSCLC metastasis by targeting MIEN1 via NF-kappaB/MMP-9/VEGF pathways, implicating a potential prognostic biomarker and therapeutic target for NSCLC treatment. (PMID:26827826)
• Data show that migration and invasion enhancer 1 (MIEN1) plays an essential role in maintaining the plasticity of the dynamic membrane-associated actin cytoskeleton, which leads to an increase in cell motility, suggesting targeting MIEN1 might represent a promising means to prevent breast tumor metastasis. (PMID:27462783)
• these results suggest the MIEN1 promoter has a short interspersed nuclear Alu element region that is hypermethylated in normal cells leading to repression of the gene; in cancer, the hypomethylation of a part of this repeat, in addition to the binding of USF, results in MIEN1 expression (PMID:27589566)
• indicate that MIEN1 overexpression may facilitate migration and invasion in breast cancer (PMID:28198505)
• Down-regulation of C35 decreased the cell viability and migration of breast ductal carcinoma cells. (PMID:28859163)
• data identified that the promotion of gastric cancer (GC) growth and metastasis induced by circRNA_100876 interacted with miR-136 and MIEN1, indicating an emerging announcement for uncovering the potential mechanism of GC progression (PMID:32305633)
• MiR-124-5p Inhibits the Progression of Gastric Cancer by Targeting MIEN1. (PMID:33349155)
• Short peptides based on the conserved regions of MIEN1 protein exhibit anticancer activity by targeting the MIEN1 signaling pathway. (PMID:38272230)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	selenow2a	ENSDARG00000038228
danio_rerio	selenow2b	ENSDARG00000089936
mus_musculus	Mien1	ENSMUSG00000002580
rattus_norvegicus	Mien1	ENSRNOG00000007227
drosophila_melanogaster	CG15456	FBGN0040650

Paralogs (2): SELENOW (ENSG00000178980), SELENOV (ENSG00000186838)

Protein

Protein identifiers

Migration and invasion enhancer 1 — Q9BRT3 (reviewed: Q9BRT3)

Alternative names: HBV X-transactivated gene 4 protein, HBV XAg-transactivated protein 4, Protein C35

All UniProt accessions (2): J3KTI2, Q9BRT3

UniProt curated annotations — full annotation on UniProt →

Function. Increases cell migration by inducing filopodia formation at the leading edge of migrating cells. Plays a role in regulation of apoptosis, possibly through control of CASP3. May be involved in a redox-related process.

Subunit / interactions. Interacts with GPX1.

Subcellular location. Cytoplasm. Cytosol. Cell membrane.

Tissue specificity. Among normal tissues, present only in Leydig cells. Strongly up-regulated in breast cancers and in brain cancer distant metastasis (at protein level). Up-regulated in prostate cancer cells and in the higher grades of prostate adenocarcinoma (at protein level).

Post-translational modifications. Isoprenylation facilitates association with the plasma membrane and enhances the migratory phenotype of cells by inducing increased filopodia formation.

Similarity. Belongs to the SelWTH family.

RefSeq proteins (2): NP_001317135, NP_115715* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011893	Selenoprotein_Rdx-typ	Family
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR051441	SelW_related	Family

Pfam: PF10262

UniProt features (22 total): strand 5, turn 4, helix 3, mutagenesis site 2, initiator methionine 1, chain 1, propeptide 1, region of interest 1, compositionally biased region 1, modified residue 1, lipid moiety-binding region 1, disulfide bond 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2LJK	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BRT3-F1	75.79	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 112

Disulfide bonds (1): 30–33

Mutagenesis-validated functional residues (2):

Position	Phenotype
112–115	no effect on subcellular location. low protein abundance, suggesting that stability is affected.
112	abolishes prenylation. predominantly cytosolic with little plasma membrane-associated expression. reduces cell migration

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 124 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, SHEPARD_BMYB_MORPHOLINO_DN, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_FILOPODIUM_ASSEMBLY, MODULE_480, WTGAAAT_UNKNOWN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, SANSOM_APC_TARGETS_DN, GOBP_CELL_PROJECTION_ORGANIZATION, GOBP_REGULATION_OF_CELL_PROJECTION_ASSEMBLY, GOBP_REGULATION_OF_FILOPODIUM_ASSEMBLY

GO Biological Process (4): apoptotic process (GO:0006915), positive regulation of cell migration (GO:0030335), negative regulation of apoptotic process (GO:0043066), positive regulation of filopodium assembly (GO:0051491)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): mitochondrion (GO:0005739), cytosol (GO:0005829), plasma membrane (GO:0005886), cytoplasmic side of plasma membrane (GO:0009898), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoplasm	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
filopodium assembly	1
regulation of filopodium assembly	1
positive regulation of plasma membrane bounded cell projection assembly	1
binding	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
plasma membrane	1
cytoplasmic side of membrane	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

932 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MIEN1	SELENOT	P62341	876
MIEN1	SELENOW	P63302	831
MIEN1	PGAP3	Q96FM1	766
MIEN1	ERBB2	P04626	764
MIEN1	GRB7	Q14451	720
MIEN1	POLR3F	Q9H1D9	704
MIEN1	STARD3	Q14849	675
MIEN1	PRDX1	P35703	645
MIEN1	TCAP	O15273	578
MIEN1	GPX6	P59796	561
MIEN1	GPX7	Q96SL4	561
MIEN1	CD82	P27701	557
MIEN1	GPX5	O75715	554
MIEN1	GPX8	Q8TED1	544
MIEN1	GPX2	P18283	542

IntAct

57 interactions, top by confidence:

A	B	Type	Score
HMGB2	MIEN1	psi-mi:“MI:0915”(physical association)	0.710
HMGB2	MIEN1	psi-mi:“MI:0914”(association)	0.710
MIEN1	REL	psi-mi:“MI:0915”(physical association)	0.560
REL	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
ZBTB32	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
TRIP6	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
POU6F2	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
HDAC7	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
ARID5A	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
VENTX	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
DDIT4L	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
MIEN1	GORASP2	psi-mi:“MI:0915”(physical association)	0.560
HLX	MIEN1	psi-mi:“MI:0915”(physical association)	0.560
MIEN1	PCBP4	psi-mi:“MI:0915”(physical association)	0.400
MIEN1	NLGN3	psi-mi:“MI:0915”(physical association)	0.370
HMGB1	MIEN1	psi-mi:“MI:0915”(physical association)	0.370
SCCPDH	PGRMC1	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
MIEN1	ZBTB32	psi-mi:“MI:0915”(physical association)	0.000
MIEN1	TRIP6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (25): MIEN1 (Two-hybrid), MIEN1 (Affinity Capture-RNA), MIEN1 (Affinity Capture-RNA), MIEN1 (Affinity Capture-MS), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), MIEN1 (Two-hybrid), DDIT4L (Two-hybrid)

ESM2 similar proteins: B9N1F9, O09171, O14929, O22718, O35490, O80526, P11029, P11497, P19803, P21343, P52565, P83468, Q0IIL1, Q0J035, Q13085, Q148C8, Q28007, Q28559, Q28943, Q2QNG7, Q2QZ86, Q32PA4, Q3ZBE1, Q4R4J0, Q4R4U1, Q4R518, Q5I597, Q5R5F8, Q5RCR8, Q5RFG2, Q5SRX1, Q5SWU9, Q5XI73, Q5ZID6, Q5ZMQ0, Q6P6Q9, Q6ZVM7, Q8L5Y9, Q8VCX5, Q923S8

Diamond homologs: D0EYG3, O19097, P59797, P63300, P63301, P63302, P63303, Q148C8, Q568W0, Q5NVB2, Q95KL4, Q9BRT3, Q9CQ86, Q9STZ2, Q19892, Q9BN19

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

10 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	7
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

265 predictions. Top by Δscore:

Variant	Effect	Δscore
17:39729757:GGCAC:G	acceptor_gain	1.0000
17:39729758:GCAC:G	acceptor_gain	1.0000
17:39729759:CAC:C	acceptor_gain	1.0000
17:39729759:CACC:C	acceptor_gain	1.0000
17:39729760:ACCTG:A	acceptor_loss	1.0000
17:39729762:C:CC	acceptor_gain	1.0000
17:39729765:G:C	acceptor_gain	1.0000
17:39729765:G:GC	acceptor_gain	1.0000
17:39730188:CCTCA:C	donor_loss	1.0000
17:39730189:CTCAC:C	donor_loss	1.0000
17:39730193:C:CA	donor_loss	1.0000
17:39729684:CAT:C	donor_gain	0.9900
17:39729760:AC:A	acceptor_gain	0.9900
17:39729761:CCTGG:C	acceptor_gain	0.9900
17:39730192:A:AC	donor_gain	0.9900
17:39730193:C:CC	donor_gain	0.9900
17:39730289:TCA:T	acceptor_gain	0.9900
17:39730290:CA:C	acceptor_gain	0.9900
17:39730290:CAC:C	acceptor_gain	0.9900
17:39730292:C:CC	acceptor_gain	0.9900
17:39730413:TC:T	donor_gain	0.9900
17:39730414:CC:C	donor_gain	0.9900
17:39729606:C:CC	acceptor_gain	0.9800
17:39729774:C:CT	acceptor_gain	0.9800
17:39730287:GTTCA:G	acceptor_gain	0.9800
17:39730401:GCTC:G	donor_loss	0.9800
17:39730402:CT:C	donor_loss	0.9800
17:39730403:TCACC:T	donor_loss	0.9800
17:39730404:C:CC	donor_loss	0.9800
17:39730405:ACCAG:A	donor_loss	0.9800

AlphaMissense

738 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:39729724:G:C	F75L	1.000
17:39729724:G:T	F75L	1.000
17:39729726:A:G	F75L	1.000
17:39729754:A:C	F65L	0.999
17:39729754:A:T	F65L	0.999
17:39729756:A:G	F65L	0.999
17:39729700:A:C	F83L	0.998
17:39729700:A:T	F83L	0.998
17:39729702:A:G	F83L	0.998
17:39729723:A:G	S76P	0.998
17:39729725:A:G	F75S	0.998
17:39729596:C:G	A92P	0.997
17:39729701:A:G	F83S	0.997
17:39729755:A:G	F65S	0.997
17:39729698:G:T	P84H	0.996
17:39729718:C:A	K77N	0.996
17:39729718:C:G	K77N	0.996
17:39729722:G:A	S76F	0.996
17:39729726:A:T	F75I	0.996
17:39729755:A:C	F65C	0.996
17:39730276:G:C	F35L	0.996
17:39730276:G:T	F35L	0.996
17:39730278:A:G	F35L	0.996
17:39729699:G:A	P84S	0.995
17:39729726:A:C	F75V	0.995
17:39729749:A:T	I67K	0.995
17:39730256:A:G	L42P	0.995
17:39729604:A:G	L89P	0.994
17:39729701:A:C	F83C	0.994
17:39730254:C:G	A43P	0.994

dbSNP variants (sampled 300 via entrez): RS1000298507 (17:39731547 C>G,T), RS1003838197 (17:39732174 T>C), RS1003905622 (17:39728472 C>G), RS1004002141 (17:39730927 T>G), RS1004429073 (17:39730622 C>A,T), RS1005313969 (17:39729615 T>C), RS1005925335 (17:39730870 G>T), RS1006287487 (17:39730607 C>G), RS1006884136 (17:39731955 C>A,T), RS1006934556 (17:39732166 C>T), RS1007494898 (17:39729097 G>A), RS1008997558 (17:39729095 C>T), RS1009360181 (17:39728857 A>T), RS1009889319 (17:39729852 C>G), RS1010941434 (17:39730073 A>G)

Disease associations

OMIM: gene MIM:611802 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000624_15	Ulcerative colitis	3.000000e-08
GCST003155_23	Systemic lupus erythematosus	8.000000e-09
GCST005212_9	Asthma	2.000000e-30
GCST005752_156	Systemic lupus erythematosus	2.000000e-12
GCST007564_21	Asthma or allergic disease (pleiotropy)	4.000000e-17
GCST008916_10	Asthma	5.000000e-09
GCST008916_21	Asthma	2.000000e-62
GCST008916_45	Asthma	3.000000e-10
GCST008916_86	Asthma	2.000000e-14

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	4
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression	1
arsenite	increases reaction, affects binding	1
sodium arsenite	decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
jinfukang	affects cotreatment, increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cannabidiol	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases expression	1
Lactic Acid	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2CE	HAP1 MIEN1 (-) 2	Cancer cell line	Male
CVCL_XQ54	HAP1 MIEN1 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.